000			01677nam a2200121Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
245		0	_aCharacterization and Clinical Management of Dilated Cardiomyopathy
546			_aEnglish[eng]
650			_aSCN5A||cardiac sodium channel||cardiac channelopathy||dilated cardiomyopathy||precision medicine||arrhythmias||atrial fibrillation||cardiomyopathy||heart failure||supraventricular arrhythmia||systolic dysfunction||tachycardiomyopathy||ventricular arrhythmia||left atrial strain||cardiac resynchronization therapy||muscular dystrophy||calcium||heart||gene therapy||phospholamban||Serca2a||mdx||oxidative stress||membrane stabilization||left ventricular noncompaction||congenital heart disease||congestive heart failure||non-ischemic cardiomyopathy||genetics||desmin||mitochondrial dysfunction||myopathy||whole exome sequencing||laminopathy||LMNA||biomarkers||troponin T||NT-proBNP||malignant ventricular arrhythmia||arrhythmic risk stratification||DNA methylation||alternative splicing||epigenetics||nonischemic dilated cardiomyopathy||cardiac magnetic resonance imaging||late gadolinium enhancement||long axis strain||left ventricle sphericity index||major adverse cardiovascular events||sex differences||left ventricular reverse remodelling||long-term outcomes||left ventricle non-compaction cardiomyopathy||cardiac magnetic resonance||titin||RNA binding motif protein 20 (RBM20)||sarcomere||diastolic dysfunction||phosphorylation||non-sense mRNA decay||mammalian target of rapamycin (mTOR) complex-1||duchenne muscular distrophy||n/a
700			_aMerlo, Marco
856			_uhttps://mdpi.com/books/pdfview/book/3292
942			_cEB
999			_c34988 _d34988